Dr Reddy’s aims to resume semaglutide supply by November after API fix

Dr Reddy's expects to resume semaglutide supplies by November after resolving quality issues. The company identified the root cause and plans corrective measures by September. Financial results were impacted by a provision linked to the semaglutide active pharmaceutical ingredient. Despite disruptions, Dr Reddy's maintains its growth and profitability guidance for fiscal year 2027. The drugmaker anticipates supplying millions of semaglutide units this fiscal year.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xl093uB
via IFTTT

Read More

Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% storm

Trump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufacturing and supply chain strategies. After this period, tariffs will escalate significantly, impacting export economics. Several Indian firms already have US manufacturing operations for flexibility. The next two years will shape how India serves its largest overseas pharmaceutical market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/PsQ6hON
via IFTTT

Read More

Trump announces new generic drugs tariff plan: No tariffs for 2 years, then 100%, and then 200%

For Indian exporters, the two-year tariff-free period offers additional time to reassess supply chains and investment plans. While the immediate impact on exports is likely to be limited, the proposed escalation to 100% and eventually 200% tariffs could significantly alter the economics of supplying generic medicines to the US if manufacturers do not establish a stronger local production footprint.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KYmzZXp
via IFTTT

Read More

ICMR licenses cancer, vaccine technologies to Emcure, Biological E

The Indian Council of Medical Research has licensed three new biomedical technologies. These innovations aim to advance cancer treatment and infectious disease protection. One drug candidate targets precancerous cervical cells, offering a safer treatment option. Two vaccine candidates will combat major bacterial gut infections. This initiative promotes government research into practical healthcare products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gzI0XQD
via IFTTT

Read More

Glenmark sees innovative products driving 70% revenue in 5-6 years: CMD Glenn Saldanha

Glenmark anticipates innovative products will drive nearly seventy percent of its revenue. This strategic shift moves the company away from its traditional generics-led model. The company is developing next-generation products targeting oncology and other complex diseases. Glenmark aims to become a global powerhouse in oncology within ten years. Artificial intelligence will significantly accelerate drug discovery and development processes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Jktyj1a
via IFTTT

Read More

Glenmark gets USFDA nod for expanded use of RYALTRIS nasal spray

Glenmark Pharmaceuticals announced US FDA approval for RYALTRIS nasal spray. This approval expands its use to children aged six to twelve years. The nasal spray treats symptoms of seasonal allergic rhinitis effectively. RYALTRIS combines antihistamine and corticosteroid in one formulation. This marks a significant step in expanding access to the treatment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yL6MSw9
via IFTTT

Read More

Japanese drugmaker Takeda's Qdenga becomes first dengue vaccine approved in India

India's drug regulator has approved Takeda's Qdenga dengue vaccine, the first of its kind. This vaccine is expected to become available in India during the first half of 2027. Qdenga offers protection against all four dengue virus serotypes for individuals aged four to sixty. The vaccine demonstrated significant efficacy in late-stage trials, reducing cases and hospitalisations. Takeda is also partnering with Biological E to boost global manufacturing capacity for Qdenga.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uXcade9
via IFTTT

Read More